Join on WhatsApp 
Join on Telegram Rabat – The medical journal BMC Public Health has published the result of a study about the effectiveness of the Sinopharm vaccine in Morocco.
Covering a five-month period of Sinopharm use in Morocco — between February 1 and June 30 of last year, the study sought to uncover the real-world effectiveness of Sinopharm against serious or critical COVID-19 patients.
Published on Saturday, the study recalled that Morocco approved the use of the Sinopharm vaccine for COVID-19 patients in January 2021.
The medical project covered medical tests on adults aged between 18 and 99 who tested positive for COVID-19 between February and June of last year.
“RT-PCR results were individually linked with outcomes from the COVID-19 severe or critical hospitalization dataset and with vaccination histories from the national vaccination registration system,” said the medical study.
Its sample included 140,892 patients who received two doses of the Sinopharm vaccine, 1,149 people who received a booster dose, and 206,149 people who were unvaccinated.
The study concluded that people vaccinated with two doses of Sinopharm are highly protected under real-world conditions against serious or critical hospitalization among people aged between 18-59.
Moderate efficacy was noticed among people aged 60.
Meanwhile, people who received full doses of vaccines, including the booster, are deemed fully protected regardless of their age.
While Morocco’s Health Ministry recently announced the end of the fourth COVID wave in the country, authorities continue to advise citizens to get vaccinated to strengthen their immune systems and curb another resurgence of the COVID virus.
To date, around 23,380,542 have received the first and second vaccine shots in Morocco, 6,737,759 have been administered a third shot, and 36,595 have received a first dose of the COVID vaccine.
